Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ENSC
- Price
- 0.89
- Stock movement down
- -0.03 (-3.20%)
- Company name
- Ensysce Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.23M
- Ent value
- 3.86M
- Price/Sales
- 0.72
- Price/Book
- 3.69
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -4045.65%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -88.89%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ENSC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.72 |
| Price to Book | 3.69 |
| EV to Sales | 0.86 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.63M |
| EPS (TTM) | -3.80 |
| FCF per share (TTM) | -2.48 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.49M |
| Gross profit (TTM) | -4.19M |
| Operating income (TTM) | -11.04M |
| Net income (TTM) | -10.97M |
| EPS (TTM) | -3.80 |
| EPS (1y forward) | -2.23 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -93.42% |
| Operating margin (TTM) | -245.89% |
| Profit margin (TTM) | -244.48% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.67M |
| Net receivables | 4.41K |
| Total current assets | 2.93M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 3.18M |
| Accounts payable | 463.46K |
| Short/Current long term debt | 364.07K |
| Total current liabilities | 2.30M |
| Total liabilities | 2.30M |
| Shareholder's equity | 874.71K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -7.04M |
| Capital expenditures (TTM) | 123.64K |
| Free cash flow (TTM) | -7.17M |
| Dividends paid (TTM) | 290.00M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -1254.46% |
| Return on Assets | -345.12% |
| Return on Invested Capital | -885.78% |
| Cash Return on Invested Capital | -578.65% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.94 |
| Daily high | 0.94 |
| Daily low | 0.86 |
| Daily Volume | 91K |
| All-time high | 23.99 |
| 1y analyst estimate | 19.23 |
| Beta | 1.16 |
| EPS (TTM) | -3.80 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ENSC | S&P500 | |
| Current price drop from All-time high | -96.30% | -0.89% |
| Highest price drop | -99.30% | -19.00% |
| Date of highest drop | 15 Oct 2024 | 8 Apr 2025 |
| Avg drop from high | -88.30% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.23M
Marketcap category
Small-cap
Description
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Employees
7
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page